RE: SNG NHS Trial.18 Mar 2020 16:27
Guardian Politics live
The UK biotech Synairgen has joined the global race to come up with a treatment for Covid-19. It has received the green light from UK regulators to conduct a trial of its lead drug SNG001 in Covid-19 patients “to potentially assist with the global outbreak of the virus”.
The inhaled drug is being developed for chronic-obstructive pulmonary disorder (COPD), a severe lung disease. In the phase 2 (intermediate) trial, 100 patients with coronavirus will be given the drug across a number of NHS trusts. The trial is expected to start imminently.
The treatment is designed to boost the patient’s immune system to help them fight off the virus. It contains interferon beta, a naturally occurring protein, which orchestrates the body’s antiviral responses. It was identified in a WHO analysis of potential Covid-19 treatments last month as the only phase 2 therapy that is inhaled.
Prof Stephen Holgate, Medical Research Council professor of immunopharmacology, said:
The reduced innate immune response that exists in the lung of those at most risk of serious Covid-19 disease such as older people and those with pre-existing lung disease makes such patients ideal candidates to receive inhaled SNG001 to replace their interferon deficiency … In the absence of a suitable vaccine, increasing the host’s own immunity to enhance protection and virus elimination would seem a logical therapeutic approach.
Synairgen was founded by three professors at the University of Southampton in 2004 and focuses on asthma and COPD. It is listed on the London stock exchange’s junior AIM market.